| Literature DB >> 30310366 |
Jae Ri Kim1, Kyoung-Bun Lee2, Wooil Kwon1, Eunjung Kim1, Sun-Whe Kim1, Jin-Young Jang1.
Abstract
BACKGROUND: Intraductal papillary neoplasm of the bile duct (IPNB) is a recently defined entity and its clinical characteristics and classifications have yet to be established. We aimed to clarify the clinical features of IPNB and determine the optimal morphological classification criteria.Entities:
Keywords: Bile Duct Neoplasms; Cholangiocarcinoma; Classification; Extrahepatic Bile Ducts; Intrahepatic Bile Ducts
Mesh:
Year: 2018 PMID: 30310366 PMCID: PMC6179985 DOI: 10.3346/jkms.2018.33.e266
Source DB: PubMed Journal: J Korean Med Sci ISSN: 1011-8934 Impact factor: 2.153
Fig. 1Modified anatomical classification.
Patients' characteristics
| Characteristics | Value | ||
|---|---|---|---|
| Clinical characteristics (n = 112) | |||
| Age, yr | 65.9 ± 8.5 | ||
| Sex, male:female | 70:42 | ||
| IHD stone | 9 (8.0%) | ||
| CS infection | 15 (13.4%) | ||
| Preop CA 19-9, median (range) | 18.5 (0.0–61000.0) | ||
| Operation name | |||
| Hilar resection | 14 (12.5%) | ||
| Right liver resection | 27 (24.1%) | ||
| Left liver resection | 37 (33.0%) | ||
| PPPD/whipple | 26 (23.2%) | ||
| Other operation | 8 (7.1%) | ||
| Operation type | |||
| Hepatobiliary resection | 68 (60.7%) | ||
| Bile duct resection | 18 (16.1%) | ||
| Pancreatoduodenectomy | 26 (23.2%) | ||
| Recur | 12 (10.7%) | ||
| Median follow-up, range (mon) | 42.8 (1.3–160.90) | ||
| Pathologic characteristics (n = 112) | |||
| Size, cm | 3.7 ± 2.2 | ||
| Histologic subtype | |||
| Gastric | 18 (16.5%) | ||
| Intestinal | 53 (48.6%) | ||
| Pancreatobiliary | 33 (30.3%) | ||
| Oncocytic | 5 (4.6%) | ||
| Histologic grade | |||
| Moderate dysplasia | 3 (2.7%) | ||
| Invasive carcinoma | 109 (97.3%) | ||
| Depth of invasion | |||
| Confined to BD | 74 (66.1%) | ||
| Beyond BD | 37 (33.0%) | ||
| Resection margin | |||
| Over HGD | 12 (10.7%) | ||
| Carcinoma | 7 (6.3%) | ||
| Lymph node metastasis | 6 (8.2%) | ||
| Angiolymphatic invasion | 11 (12.9%) | ||
| Vascular invasion | 10 (9.5%) | ||
| Perineural invasion | 14 (15.4%) | ||
IHD = intrahepatic bile duct, CS = Clonorchis sinensis, CA 19-9 = cancer antigen 19-9, PPPD = pylorus-preserving pancreaticoduodenectomy, BD = bile duct, HGD = high-grade dysplasia.
Fig. 2Overall survival of total patients.
Fig. 3Overall survival according to the various prognostic factors. (A) Overall survival according to the histologic subtypes. (B) Overall survival according to the JBA classification.10 (C) Overall survival according to the classification by Kim et al.9 (D) Overall survival according to the modified anatomical classification. (E) Overall survival according to the resection margin status. (F) Overall survival according to the lymph node metastasis.
JBA = Japan Biliary Association.
Prognostic factors for survival
| Parameters | Univariate analysis | Multivariate analysis | ||||
|---|---|---|---|---|---|---|
| OR (95% CI) | EXP (B) | 95% CI | ||||
| Age, yr | ||||||
| ≥ 65 | 1.775 (0.674–4.674) | 0.242 | ||||
| CA 19-9 | ||||||
| ≥ 37 | 2.091 (0.850–5.147) | 0.105 | ||||
| Positive RM | 5.030 (1.048–24.155) | 0.028 | 6.918 | 1.076–38.093 | 0.041 | |
| Grade | ||||||
| Carcinoma/dysplasia | 1.313 (1.182–1.459) | 0.334 | ||||
| Depth beyond the bile duct | 1.664 (0.674–4.112) | 0.267 | ||||
| Lymph node metastasis | 4.154 (0.751–22.990) | 0.083 | ||||
| Histologic subtype | ||||||
| IT + GT/others | 1.227 (0.477–3.155) | 0.670 | ||||
| Location of the main lesion | ||||||
| Extrahepatic + diffuse/others | 1.620 (0.635–4.133) | 0.310 | ||||
| Angiolymphatic invasion | 0.388 (0.046–3.241) | 0.376 | ||||
| Vascular invasion | 2.500 (0.695–10.483) | 0.175 | ||||
| Perineural invasion | 12.060 (3.355–43.345) | < 0.001 | 12.281 | 3.265–46.194 | < 0.001 | |
OR = odds ratio, CI = confidence interval, CA 19-9 = cancer antigen 19-9, RM = resection margin, IT = intestinal type, GT = gastric type.
Clinicopathologic characteristics according to morphological and anatomical classifications
| Parameters | Modified anatomical classification | Classification by the JBA | Classification by Kim et al. | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| EH | IH | Diffuse | I | II | III | IV | I | II | III | IV | V | UC | ||||||
| Cystic | Duct-ectatic | |||||||||||||||||
| Case | 48 (41) | 10 (9) | 34 (30) | 22 (23) | 52 (46) | 49 (44) | 9 (8) | 2 (2) | 55 (49) | 3 (3) | 39 (34) | 2 (2) | 5 (5) | 9 (8) | ||||
| Age, > 65 yr | 32 (71) | 5 (50) | 19 (56) | 15 (65) | 0.426 | 29 (56) | 36 (74) | 5 (56) | 1 (50) | 0.279 | 36 (66) | 3 (100) | 22 (58) | 1 (50) | 5 (100) | 4 (44) | 0.239 | |
| Sex, male:female | 27:18 | 8:2 | 22:12 | 13:10 | 0.605 | 33:19 | 29:20 | 7:2 | 1:1 | 0.734 | 30:25 | 1:2 | 27:11 | 2:0 | 3:2 | 7:2 | 0.319 | |
| CA 19-9, > 37 | 15 (33) | 1 (10) | 12 (35) | 9 (39) | 0.413 | 17 (46) | 18 (49) | 2 (5) | 0 (0) | 0.622 | 18 (49) | 2 (5) | 13 (35) | 1 (3) | 2 (5) | 1 (3) | 0.566 | |
| OP type | < 0.001 | < 0.001 | < 0.001 | |||||||||||||||
| HBR | 4 (9) | 9 (90) | 34 (100) | 21 (91) | 43 (83) | 15 (31) | 8 (89) | 2 (100) | 15 (27) | 3 (100) | 36 (95) | 2 (100) | 4 (80) | 8 (89) | ||||
| BDR | 15 (33) | 1 (10) | 0 (0) | 2 (9) | 2 (4) | 15 (31) | 1 (11) | 0 (0) | 14 (26) | 0 (0) | 2 (5.3) | 0 (0) | 1 (20) | 1 (11) | ||||
| PD | 26 (58) | 0 (0) | 0 (0) | 0 (0) | 7 (14) | 19 (39) | 0 (0) | 0 (0) | 26 (47) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | ||||
| Beyond BD | 13 (29) | 2 (20) | 11 (32) | 11 (50) | 0.265 | 14 (28) | 21 (43) | 2 (22) | 0 (0) | 0.231 | 20 (36) | 1 (33) | 12 (32) | 0 (0) | 2 (40) | 2 (22) | 0.871 | |
| LN metastasis | 5 (12) | 0 (0) | 0 (0) | 1 (7) | 0.525 | 1 (4) | 5 (12) | 0 (0) | 0.361 | 5 (10) | 0 (0) | 1 (6) | 0 (0) | 0 (0) | 0.879 | |||
| Positive RM | 3 (7) | 0 (0) | 0 (0) | 4 (17) | 0.050 | 2 (4) | 5 (10) | 0 (0) | 0 (0) | 0.466 | 5 (9) | 0 (0) | 1 (3) | 0 (0) | 1 (20) | 0 (0) | 0.528 | |
| Grade | 0.904 | 0.313 | < 0.001 | |||||||||||||||
| Dysplasia | 1 (2) | 0 (0) | 1 (3) | 1 (4) | 3 (6) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 1 (3) | 1 (50) | 1 (20) | 0 (0) | ||||
| Carcinoma | 44 (98) | 10 (100) | 33 (97) | 22 (96) | 49 (94) | 49 (100) | 9 (100) | 2 (100) | 55 (100) | 3 (100) | 37 (97) | 1 (50) | 4 (80) | 9 (100) | ||||
| Histologic subtype | 0.002 | 0.009 | 0.183 | |||||||||||||||
| GT | 4 (9) | 2 (20) | 4 (12) | 8 (36) | 9 (17) | 7 (15) | 2 (22) | 0 (0) | 9 (17) | 0 (0) | 7 (18) | 0 (0) | 0 (0) | 2 (22) | ||||
| IT | 32 (71) | 2 (20) | 15 (44) | 6 (27) | 20 (39) | 33 (69) | 1 (11) | 1 (50) | 34 (63) | 2 (67) | 13 (34) | 1 (50) | 3 (60) | 2 (22) | ||||
| PT | 9 (20) | 4 (40) | 13 (38) | 3 (32) | 21 (40) | 7 (15) | 4 (44) | 1 (50) | 10 (19) | 1 (33) | 16 (42) | 1 (50) | 2 (40) | 3 (33) | ||||
| OT | 0 (0) | 2 (20) | 2 (6) | 1 (5) | 2 (4) | 1 (2) | 2 (22) | 0 (0) | 1 (2) | 0 (0) | 2 (5) | 0 (0) | 0 (0) | 2 (22) | ||||
Data are presented as number (%).
UC = unclassified, EH = extrahepatic, IH = intrahepatic, CA 19-9 = cancer antigen 19-9, HBR = hepatobiliary resection, BDR = bile duct resection, PD = pancreaticoduodenectomy, BD = bile duct, LN = lymph node, RM = resection margin, GT = gastric type, IT = intestinal type, PT = pancreatobiliary type, OT = oncocytic type.